Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
LRP5L Biologics Sequence Review Report 2026: Low-density lipoprotein receptor-related protein 5-like protein Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of LRP5L protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
LRP11 Biologics Sequence Review Report 2026: Low-density lipoprotein receptor-related protein 11 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of LRP11 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
KLRG2 Biologics Sequence Review Report 2026: Killer cell lectin-like receptor subfamily G member 2 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of KLRG2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
KLRG1 Biologics Sequence Review Report 2026: Killer cell lectin-like receptor subfamily G member 1 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of KLRG1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
KLRF2 Biologics Sequence Review Report 2026: Killer cell lectin-like receptor subfamily F member 2 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of KLRF2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
KLRF1 Biologics Sequence Review Report 2026: Killer cell lectin-like receptor subfamily F member 1 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of KLRF1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
ILKAP Biologics Sequence Review Report 2026: Integrin-linked kinase-associated serine/threonine phosphatase 2C Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of ILKAP protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
ILF2 Biologics Sequence Review Report 2026: Interleukin enhancer-binding factor 2 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of ILF2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
IL37 Biologics Sequence Review Report 2026: Interleukin-37 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of IL37 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
IL34 Biologics Sequence Review Report 2026: Interleukin-34 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of IL34 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
IL27 Biologics Sequence Review Report 2026: Interleukin-27 subunit alpha Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of IL27 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
IL26 Biologics Sequence Review Report 2026: Interleukin-26 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of IL26 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.